Principal Financial Group Inc. Acquires 4,431,897 Shares of Sabra Healthcare REIT, Inc. $SBRA

Key Points

• Principal Financial Group boosted its stake in Sabra by 21.6%, purchasing 4,431,897 shares to own 24,953,351 shares (10.01% of the company) valued at about $472.6 million.
• Sabra posted Q EPS of $0.16 (in line) and revenue of $221.75M (beat estimates), with revenue up 20.9% YoY and FY2026 guidance of $1.55–$1.59 EPS; analysts hold a consensus "Moderate Buy" with an average target of $22.00.
• The company announced a $0.30 quarterly dividend (annualized $1.20), a 5.9% yield, but the dividend payout ratio is a high 190.48%, indicating the payout exceeds current earnings.

Principal Financial Group Inc. lifted its holdings in shares of Sabra Healthcare REIT, Inc. (NASDAQ:SBRA - Free Report) by 21.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,953,351 shares of the real estate investment trust's stock after purchasing an additional 4,431,897 shares during the period. Principal Financial Group Inc. owned 10.01% of Sabra Healthcare REIT worth $472,617,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in SBRA. Founders Capital Management bought a new stake in shares of Sabra Healthcare REIT during the 3rd quarter valued at about $28,000. Danske Bank A S bought a new stake in shares of Sabra Healthcare REIT during the 3rd quarter valued at about $30,000. Larson Financial Group LLC raised its stake in Sabra Healthcare REIT by 42.3% during the 3rd quarter. Larson Financial Group LLC now owns 1,860 shares of the real estate investment trust's stock worth $35,000 after buying an additional 553 shares during the period. First Horizon Corp acquired a new position in Sabra Healthcare REIT during the 4th quarter worth approximately $44,000. Finally, Covestor Ltd raised its stake in Sabra Healthcare REIT by 23,720.0% during the 3rd quarter. Covestor Ltd now owns 2,382 shares of the real estate investment trust's stock worth $45,000 after buying an additional 2,372 shares during the period. Institutional investors own 99.40% of the company's stock.

Sabra Healthcare REIT Stock Performance

Shares of Sabra Healthcare REIT stock opened at $20.46 on Tuesday. The company has a market cap of $5.16 billion, a PE ratio of 32.48, a price-to-earnings-growth ratio of 1.63 and a beta of 0.67. Sabra Healthcare REIT, Inc. has a 52 week low of $17.04 and a 52 week high of $21.07. The business has a 50 day moving average price of $20.23 and a 200-day moving average price of $19.36. The company has a quick ratio of 4.72, a current ratio of 4.72 and a debt-to-equity ratio of 0.96.

Sabra Healthcare REIT (NASDAQ:SBRA - Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The real estate investment trust reported $0.16 EPS for the quarter, hitting the consensus estimate of $0.16. The firm had revenue of $221.75 million during the quarter, compared to the consensus estimate of $209.20 million. Sabra Healthcare REIT had a return on equity of 5.60% and a net margin of 19.22%.The company's quarterly revenue was up 20.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.37 earnings per share. Sabra Healthcare REIT has set its FY 2026 guidance at 1.550-1.590 EPS. Equities analysts anticipate that Sabra Healthcare REIT, Inc. will post 1.5 earnings per share for the current fiscal year.

Sabra Healthcare REIT Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 29th. Stockholders of record on Friday, May 15th will be paid a $0.30 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $1.20 annualized dividend and a dividend yield of 5.9%. Sabra Healthcare REIT's dividend payout ratio is 190.48%.

Analyst Upgrades and Downgrades

SBRA has been the topic of a number of research reports. Truist Financial upped their price target on Sabra Healthcare REIT from $21.00 to $22.00 and gave the stock a "hold" rating in a research note on Friday, March 13th. Citigroup upped their price target on Sabra Healthcare REIT from $21.00 to $24.00 and gave the stock a "buy" rating in a research note on Wednesday, February 18th. Wall Street Zen raised Sabra Healthcare REIT from a "sell" rating to a "hold" rating in a research note on Saturday. Scotiabank upped their price target on Sabra Healthcare REIT from $20.00 to $21.00 and gave the stock a "sector perform" rating in a research note on Monday, March 2nd. Finally, Cantor Fitzgerald upped their price target on Sabra Healthcare REIT from $20.00 to $21.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 17th. Five research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $22.00.

About Sabra Healthcare REIT

Sabra Healthcare REIT, Inc NASDAQ: SBRA is a real estate investment trust that acquires, owns and operates net‐lease healthcare properties. Its diversified portfolio spans senior housing communities, skilled nursing and rehabilitation centers, outpatient medical facilities, medical office buildings, hospitals and life science properties. Sabra structures long‐term, triple‐net lease agreements with healthcare operators, providing stable rental income streams while allowing tenants to focus on patient care and operational excellence.

Serving a broad spectrum of care segments, Sabra's tenants include both regional and national providers of assisted living, independent living, memory care, post‐acute rehabilitation and research and development laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.